Akero Therapeutics Inc logo

AKRO - Akero Therapeutics Inc Share Price

$23.47 0.5  2.3%

Last Trade - 5:42pm

Sector
Healthcare
Size
Mid Cap
Market Cap £502.1m
Enterprise Value £388.8m
Revenue £n/a
Position in Universe 2807th / 6416
Bullish
Bearish
Unlock AKRO Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AKRO Revenue Unlock AKRO Revenue

Net Income

AKRO Net Income Unlock AKRO Revenue

Normalised EPS

AKRO Normalised EPS Unlock AKRO Revenue

PE Ratio Range

AKRO PE Ratio Range Unlock AKRO Revenue

Dividend Yield Range

AKRO Dividend Yield Range Unlock AKRO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AKRO EPS Forecasts Unlock AKRO Revenue
Profile Summary

Akero Therapeutics, Inc. is a clinical-stage biotechnology company that is focused on developing and commercializing treatments for serious metabolic diseases. The Company is engaged in nonalcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. The Company’s lead product candidate, AKR-001, which the Company is developing as a treatment for patients with NASH, is an analog of fibroblast growth factor 21 (FGF21). FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated January 24, 2017
Public Since June 20, 2019
No. of Shareholders: n/a
No. of Employees: 10
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 28,558,653
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AKRO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AKRO
Upcoming Events for AKRO
Similar to AKRO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.